Controlled joint venture GBM-V is based at a 135 sq ft facility in Rostock, Germany. Responsible for human tissue production within Europe, GBM-V is negotiating the regulatory pathway for the introduction of CardioPure decellularised pulmonary and aortic heart valves into the European market. It is also the region’s first ‘multi-tissue’ bank and is currently responsible for the retrieval and distribution of donated Cornea.